Recent investigations have centered on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopamine neurotransmission. While GIP stimulators are commonly employed for treating type 2 diabetes, their emerging consequences on motivation circuits, specifically mediated by dopami